Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOV: Olaparib with HIPEC in Ovarian Cancer
NCT07460180Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Netherlands Cancer Institute. Started May 2025; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07460180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460180.